Objective: Coreceptors are important for HIV-1 entry into target cells and disease progression. The impact of HIV-1 and highly active antiretroviral treatment (HAART) on coreceptor expression has been little studied. Methods: Expression of C-C chemokine receptor (CCR) 5 and C-X-C chemokine receptor (CXCR) 4 on CD4þ and CD8 þ T cells was compared in HIV-1-infected individuals who had/had not received HAART, and in healthy controls. Relationships between coreceptors and their chemokine ligands were studied. Results: This study included 23 controls and 88 HIV-1-infected individuals, 35 of whom were HAART naïve. Percentages of CCR5 and CXCR4þ CD8 þ T cells were higher, and CXCR4þ CD4 þ T cells were lower, in patients than in controls. Patients receiving HAART showed a higher percentage of CCR5 expression on CD4 þ T cells compared with HAART-naïve patients. HIVinfected individuals had significantly increased levels of peripheral ligands for coreceptors, compared with controls; levels were significantly higher in those receiving HAART compared with the HAART-naïve.
Introduction
Major targets for HIV-1 infection are cells expressing CD4 molecules and with C-C chemokine receptor (CCR) type 5 and C-X-C chemokine receptor (CXCR) type 4 coreceptors on their surfaces. 1 The b-chemokine receptor CCR5 is the major coreceptor for macrophage (M)-tropic (R5) strains of HIV-1, 2,3 whereas the a-chemokine receptor, CXCR4, facilitates entry of T-tropic (X4) HIV-1 strains. 4 M-tropic strains of HIV-1 infect cells of myeloid lineage, primary CD4þ T cells, but not Tcell lines in vitro. 5, 6 In addition, M-tropic strains of HIV-1do not induce syncytium formation, replicate slowly compared with syncytium-inducing (SI) strains, 7 and can be isolated at all stages of disease. 8 T-tropic strains of HIV-1 have SI phenotypes, are more cytopathic than M-tropic strains, and generally emerge at later (compared with earlier) stages of HIV-1 infection. 9 Some primary isolates of HIV-1 may be dual tropic, using either CXCR4 or CCR5 for fusion with primary macrophages. 10 Expression of coreceptors is very important for the progression of HIV infection. A deletion in the wild-type CCR5 allele produces the mutant allele CCR5-Á32, which encodes a nonfunctional, truncated CCR5 receptor that confers protection against HIV-1 infection in vivo. 11 Individuals who are homozygous for CCR5-Á32 are highly resistant to HIV-1 infection, whereas heterozygosity for CCR5-Á32 delays disease progression by an average of 2 years. 12 The b-chemokines are secreted by a wide variety of cells including monocyte/macrophages, T cells, Ebroblasts and mast cells. 12 They promote chemotaxis, leucocyte trafEcking, inFammation and haematopoiesis. 13 Natural ligands for CCR5 have been identified as b-chemokine regulated upon activation, normal T-cell expressed and secreted (RANTES). 14 b-chemokines are important inhibitors of R5 strains of HIV-1 in cells of macrophage lineage. 15 Treatment of monocyte-derived macrophages in vitro with b-chemokines inhibits CCR5 expression, HIV-1 entry, viral production and uncoating. 3, 14 The a-chemokines, stromal cell-derived factor (SDF)-1a and SDF-1b are natural ligands for CXCR4, which are also inhibitors of X5 strains of HIV-1, in CD4 þ T cells. [16] [17] [18] Highly active antiretroviral treatment (HAART) can provide effective treatment for acquired immune deficiency syndrome (AIDS). HAART can effectively suppress HIV replication, rebuild the immune system and considerably improve the prognosis of patients. 19, 20 The impact of HAART on the expression of coreceptors in individuals infected with HIV-1 has not been well studied. Here, the expression of CCR5 and CXCR4 on CD4þ and CD8 þ T cells was compared between controls and individuals infected with HIV-1who had, or had not, received HAART. In addition, the relationships between coreceptors and their chemokine ligands were investigated.
Patients and methods

Study population
Individuals with HIV-1 infection were sequentially recruited from outpatients visiting the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, between September 2010 and January 2012. The enrolment criteria for individuals were being HIV-1 positive, >18 years of age and without other sexually transmitted infections. HIV-1 infection was diagnosed on the basis of positive serological and HIV-1 RNA detection assays; AIDS was diagnosed based on the Centers for Disease Control and Prevention (CDC) classification system for HIV-1 infection. 21 Patients were classified into a CDC category based on their CD4 count: those with a CD4 count >500/ml were classified as CDC A, those with a CD4 count 500/ml and >200/ ml were classified as CDC B and those with a CD4 count 200/ml were classified as CDC C. Details of any prescription of HAART was recorded for each patient. Patients who had had opportunistic infections diagnosed in the 3 months before enrolment were excluded from the study.
In addition, this study included apparently healthy controls enrolled from local primary healthcare clinics Health records were reviewed to ensure that control subjects were age-, sex-and ethnically matched with the participants with HIV-1 infection, and had no diagnosed diseases reported in the 3 months before study enrolment. All control subjects were tested and confirmed to be HIV-1-negative. Written informed consent was obtained from all participants. This study was approved by the Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Flow cytometry
Venous blood (2 ml) was collected from each participant into tubes containing ethylenediaminetetra-acetic acid. Plasma was immediately separated from whole blood by centrifugation at 400 g for 10 min at room temperature and stored at À70 C until it was used for viral load detection. The blood cells were resuspended in phosphate buffered saline (pH 7.2) and the proportion of individual blood cell types was determined by four-colour flow cytometry using a FACScan TM and a commercial flow cytometry assay (both from Becton, Dickinson & Co., Franklin Lakes, NJ, USA) according to the manufacturer's protocol. Absolute counts and percentages of CD3 þ CD4þ and CD3 þ CD8 þ T lymphocytes were determined with anti-CD3-PC5, anti-CD4-FITC and anti-CD8-FITC antibodies (Becton, Dickinson & Co.); the amount of antibody used was in accordance with the manufacturer's specifications. Expression of CCR5 and CXCR4 on the surfaces of CD4þ/CD8 þ T lymphocytes and their naı¨ve and memory subsets were determined using anti-CD45RA-APC, anti-CD45RO-APC, anti-CCR5-PE and anti-CXCR4-PE antibodies (Becton, Dickinson & Co.); the amount of antibody used was in accordance with the manufacturer's specifications. The combinations of antibodies were:
The percentages of CCR5-or CXCR4-positive T cells and the mean fluoresence intensity (MFI) of CCR5 or CXCR4 were analysed.
Expression of coreceptors is more important for HIV-1 infection in CD4 þ T cells than in CD8 þ T cells, as CD4 þ T cells are target cells for HIV-1 infection. 1, 3 Therefore, we studied the expression of coreceptors CCR5 and CXCR4 on memory and naı¨ve subtypes of CD4 þ T cells using flow cytometry.
To explore whether expression of coreceptors was related to progression of HIV-1 infection, we further divided the patients infected with HIV-1 using the CDC classification system and studied levels of coreceptor CCR5 and CXCR4 expression in the different groups.
Quantification of HIV-1 RNA
The HIV-1 viral load in the plasma of patients with HIV-1 infection was quantitatively determined using a standardized reverse transcription-polymerase chain reaction assay (COBAS Õ Amplicor HIV-1 monitor test, version 1.5, ultrasensitive specimen preparation, Roche Diagnostic Systems, Branchburg, NJ, USA). The detection limit in plasma was defined as 50 HIV-1 RNA copies/ml.
ELISA
Levels of RANTES, SDF-1a and SDF-1b in plasma were measured by a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) using the Human CCL5/ RANTES Quantikine ELISA kit, Human CXCL12/SDF-1 alpha Quantikine ELISA kit and Human CXCL12/SDF-1 beta Biotin Affinity Purified PAb kit (all from R&D Systems, Minneapolis, MN, USA), as described by the manufacturer. Chemokine concentrations were determined by comparing samples with a standard curve.
Statistical analyses
Statistical analyses were performed using SPSS Õ for Windows version 11.5 (SPSS Inc, Chicago, Il, USA). Student's t-test was used to compare between two groups, and a oneway analysis of variance was used when comparing more than three groups.
All P-values were two-tailed and values <0.05 were considered statistically significant. Correlation was tested using Spearman's correlation coefficient.
Results
A total of 88 individuals infected with HIV-1 were recruited to this study: 53 had received HAART for >2 years and 35 were HAART naı¨ve. This study also included 23 controls. The ages of the patients and controls, their viral load details and CD4 þ T-cell counts are reported in Table 1 .
Patients with HIV-1 infection showed higher percentages of CCR5 and CXCR4 positive CD8 þ T cells (P < 0.05), but a lower percentage of CXCR4 þ CD4 þ T cells than the controls (P < 0.05). No difference was found in the MFI of CCR5 and CXCR4 expression on CD4 þ and CD8 þ T cells between individuals with HIV-1 infection and controls ( Table 2) .
The MFI results for CCR5 and CXCR4 expression on CD8 þ T cells for patients infected with HIV-1 and receiving HAART were significantly higher (P < 0.05) than that for HIV-1 patients not receiving HAART. Patients infected with HIV-1 and receiving HAART also showed an increased CCR5 expression on CD4 þ T cells, both in percentage terms and as measured by MFI, but a decreased CXCR4 expression on CD4 þ T cells as measured by MFI (P < 0.05), compared with HIV-1-infected patients who were not receiving HAART ( Table 2 ).
The percentages of both memory and naı¨ve CD4 þ T cells expressing CXCR4 from patients infected with HIV-1 were lower than that from controls (P < 0.05; Table 3 ). A higher percentage of naı¨ve CD4 þ T cells and a lower percentage of memory CD4 þ T cells expressed CCR5 in samples from patients infected with HIV-1 compared with samples from controls. No significant difference was found between the MFI of coreceptor expression for memory and naı¨ve CD4 þ T cells, between patients infected with HIV-1 and controls. There were no differences in either percentages or MFI values for coreceptor expression on memory and naı¨ve CD4 þ T cells, between patients infected with HIV-1 receiving HAART and those not receiving HAART.
Patients infected with HIV-1 were divided into three groups using the CDC classification system: CDC A, n ¼ 28; CDC B, n ¼ 34; CDC C, n ¼ 26. There was no difference in MFI of CCR5 and CXCR4 on CD4þ or CD8 þ T cells among the different CDC groups. However, the percentages of CD4 þ T cells expressing some coreceptors in the CDC B group were significantly lower than those in the CDC A or CDC C groups (P < 0.05, Table 4 ). A comparison of coreceptor expression on memory and naı¨ve CD4 þ T cells was made among patients infected with HIV-1 in different CDC categories. The percentages of memory and naı¨ve CD4 þ T cells expressing some coreceptors CCR5 and CXCR4 in samples from patients in CDC category B were significantly lower than those in CDC categories A and C (P < 0.05, Table 5 ).
Significantly increased peripheral levels of RANTES, SDF-1a, and SDF-1b, were found in patients infected with HIV-1 compared with controls ( Table 6) ; levels were significantly higher in patients who were not receiving HAART compared with those who were receiving HAART (P < 0.05; Table 6 ). Chemokine levels for patients in different CDC categories were also compared, but no significant differences were found between the categories, although levels were significantly higher in all three CDC groups compared with the control group (Table 6) . No relationship was found between chemokine levels and expression of HIV-1 coreceptors ( Table 6 ).
Discussion
Our findings presented here show that CCR5 expression was increased on T lymphocytes in patients infected with HIV-1, especially on CD8 þ T cells versus controls. CXCR4 expression was decreased on 22, 23 During the early stages and throughout HIV-1 infection, R5 strains are often detected; X4 strains typically emerge during the later stages of infection. 22, 23 Emergence of X4 strains is recognized in nearly half of patients in the advanced stages of infection and is usually accompanied by an accelerated decrease in CD4 þ T cell counts, implying an association between AIDS progression and the emergence of CXCR4-using strains. 24 Our study suggests that HAART can partly reverse the switch of coreceptor usage from CCR5 to CXCR4, especially on CD4 þ T cells. However, the mechanism by which this occurs needs to be further studied. Under normal circumstances, CCR5 expression is much higher than CXCR4 expression on memory T cells. However, the contrary is true on naı¨ve T cells: CCR5 is rarely expressed, but CXCR4 is abundantly expressed. 25 Our study found that the percentage of memory CD4 þ T cells and naı¨ve CD4 þ T cells expressing CXCR4 was significantly decreased in patients with HIV-1 infection compared with controls, but the number of coreceptors per memory and naı¨ve CD4 þ T cell was not changed. This may be due to the low viral load in our patient sample, as the HIV-1 viral load was undetectable in most of the patients infected with HIV-1. Thus, there may have been insufficient HIV-1 virus to impact the expression of coreceptors. Additionally, the low percentage of memory and naı¨ve CD4 þ T cells expressing coreceptor CXCR4 needs to be further explored. No significant differences were found in the MFI of coreceptors expressed on T cells between groups of patients from different CDC categories. Our analysis of coreceptor expression on memory and naı¨ve CD4 þ T cells from patients with different CDC severity categories of HIV-1 found that the percentage of memory and naı¨ve CD4 þ T cells expressing coreceptors was much lower in CDC B samples than in CDC A and CDC C samples. This may be related to the fast deletion of CD4 þ T cells in patients who are classified as CDC disease stage B. 26 The increase of coreceptor expression on memory and naı¨ve CD4 þ T cells in CDC stage C could be partly attributed to the infection of CD4 and CCR5 positive monocytes and macrophages by HIV-1, which could enhance coreceptor expression on CD4 þ T cells. 27 We also measured peripheral levels of RANTES, SDF-1a and SDF-1b in patients infected with HIV-1, and analysed the relationship between these ligands and coreceptor expression. We found a great increase in the chemokine levels in the serum of patients infected with HIV-1, which was partly decreased by HAART but was still higher than levels measured in control subjects. We found no relationship between chemokine levels and coreceptor expression. Our results suggest that levels of chemokines may not be related to the progression of HIV-1 infection, which is consistent with findings reported elsewhere. 28, 29 The limitations of the present study are firstly its design -it is a cross-sectional study -and secondly, the findings may have been clearer if a greater number of patients with HIV-1 infection had been recruited. Long term follow-up of the cohort is needed for further study on coreceptor expression on T cells of patients infected with HIV-1.
In conclusion, our study indicates that the expression of coreceptors on T cells can be increased by HIV infection. Treatment with HAART can increase CCR5 expression further and decrease CXCR4 expression, reversing the switch from CCR5 to CXCR4, which is more significant for CD4 þ T cells. Our results also suggest that coreceptor expression on T cells and chemokine levels are not related to HIV-1 progression.
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